Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Non-randomized Phase II Pilot Study to Assess the Efficacy and Safety of Dasatinib After Allogeneic Stem Cell Transplantation in Patients With de Novo Philadelphia Positive (Bcr-abl +) Acute Lymphoblastic Leukemia

NCT01310010 is registered in ClinicalTrials.gov with Grupo Espanol de trasplantes hematopoyeticos y terapia celular as lead sponsor.

NCT NCT01310010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01310010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Non-randomized Phase II Pilot Study to Assess the Efficacy and Safety of Dasatinib After Allogeneic Stem Cell Transplantation in Patients With de Novo Philadelphia Positive (Bcr-abl +) Acute Lymphoblastic Leukemia
Lead sponsor
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2010
Completion date
July 31, 2016
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoblastic, acute, philadelphia-positive